SAVA - CASSAVA SCIENCES INC

2.03
-0.010   -0.493%

Share volume: 676,814
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$2.04
-0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 1%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.14%
1 Month
-0.98%
3 Months
-37.35%
6 Months
-6.88%
1 Year
-23.97%
2 Year
-88.99%
Key data
Stock price
$2.03
P/E Ratio 
0.00
DAY RANGE
$1.96 - $2.04
EPS 
-$2.28
52 WEEK RANGE
$1.15 - $4.98
52 WEEK CHANGE
-$23.97
MARKET CAP 
140.576 M
YIELD 
N/A
SHARES OUTSTANDING 
48.308 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
1.64
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$608,780
AVERAGE 30 VOLUME 
$691,968
Company detail
CEO: Remi Barbier
Region: US
Website: cassavasciences.com
Employees: 30
IPO year: 2000
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial.

Recent news